EA201590397A8 - Способствующие экспрессии антигенных последовательностей у listeria партнеры для гибридизации, представляющие собой сигнальные пептиды, и способы их получения и применения - Google Patents
Способствующие экспрессии антигенных последовательностей у listeria партнеры для гибридизации, представляющие собой сигнальные пептиды, и способы их получения и примененияInfo
- Publication number
- EA201590397A8 EA201590397A8 EA201590397A EA201590397A EA201590397A8 EA 201590397 A8 EA201590397 A8 EA 201590397A8 EA 201590397 A EA201590397 A EA 201590397A EA 201590397 A EA201590397 A EA 201590397A EA 201590397 A8 EA201590397 A8 EA 201590397A8
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- partners
- hybridization
- signal peptides
- listeria
- contributing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
Abstract
В настоящем изобретении предложены нуклеиновые кислоты, системы экспрессии и вакцинные штаммы, обеспечивающие эффективную экспрессию и секрецию представляющих интерес антигенов в цитозоль клеток-хозяев и вызывающие эффективный CD4 и CD8 Т-клеточный ответ путем функционального связывания сигнальных пептидов/секреторных шаперонов Listerial или других бактерий в качестве N-концевых партнеров для гибридизации в трансляционной рамке считывания с выбранными кодируемыми рекомбинантным образом белковыми антигенами. Из указанных N-концевых партнеров для гибридизации удаляют (путем фактического удаления, путем введения мутации или с применением комбинации указанных подходов) любые последовательности PEST, встречающиеся в природе в данной последовательности, и/или определенные гидрофобные остатки.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261746237P | 2012-12-27 | 2012-12-27 | |
US201361780744P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/078119 WO2014106123A1 (en) | 2012-12-27 | 2013-12-27 | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201590397A1 EA201590397A1 (ru) | 2016-02-29 |
EA201590397A8 true EA201590397A8 (ru) | 2016-08-31 |
Family
ID=51017446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590397A EA201590397A8 (ru) | 2012-12-27 | 2013-12-27 | Способствующие экспрессии антигенных последовательностей у listeria партнеры для гибридизации, представляющие собой сигнальные пептиды, и способы их получения и применения |
Country Status (13)
Country | Link |
---|---|
US (2) | US9663557B2 (ru) |
EP (1) | EP2938627B1 (ru) |
JP (2) | JP2016503655A (ru) |
KR (1) | KR102160322B1 (ru) |
CN (1) | CN104955835B (ru) |
AU (2) | AU2013370210B2 (ru) |
BR (1) | BR112015015076A2 (ru) |
CA (1) | CA2888727A1 (ru) |
EA (1) | EA201590397A8 (ru) |
HK (1) | HK1215260A1 (ru) |
MX (1) | MX2015008329A (ru) |
SG (2) | SG11201502792TA (ru) |
WO (1) | WO2014106123A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2853269T3 (da) | 2008-05-19 | 2019-08-05 | Advaxis Inc | Dobbelt indgivelsessystem til heterologe antigener, der omfatter en rekombinant Listeria-stamme svækket ved mutation af dal/dat og deletion af ActA, der omfatter et nukleinsyremolekyle, der koder for et listeriolysin O-prostataspecifikt antigenfusionsprotein |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
CN103282048B (zh) | 2010-10-01 | 2017-05-17 | 宾夕法尼亚大学理事会 | 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途 |
CN103687611A (zh) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | 基于李斯特菌属的佐剂 |
KR20140134695A (ko) | 2012-03-12 | 2014-11-24 | 어드박시스, 인크. | 리스테리아 백신 치료 후 억제 세포 기능 저해 |
CA2955612C (en) | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
WO2016061115A1 (en) | 2014-10-13 | 2016-04-21 | Providence Health & Services-Oregon D/B/A Providence Portland Medical Center | Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof |
US10765699B2 (en) | 2015-02-06 | 2020-09-08 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
CR20170507A (es) * | 2015-04-13 | 2018-02-13 | Aduro Biotech Inc | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos. |
WO2016168214A2 (en) * | 2015-04-13 | 2016-10-20 | Aduro Biotech, Inc. | Immunogenic fusion proteins for the treatment of cancer |
WO2016184860A1 (en) * | 2015-05-18 | 2016-11-24 | Universita' Degli Studi Di Trento | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
PL3429596T3 (pl) * | 2016-03-18 | 2022-12-19 | Immune Sensor, Llc | Cykliczne związki dinukleotydowe i sposoby stosowania |
AU2017363278B2 (en) | 2016-11-22 | 2022-10-27 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
JP7284156B2 (ja) | 2017-09-19 | 2023-05-30 | アドバクシス, インコーポレイテッド | 細菌またはListeria株の凍結乾燥のための組成物および方法 |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
SG11202008820WA (en) | 2018-03-09 | 2020-10-29 | Advaxis Inc | Compositions and methods for evaluating attenuation and infectivity of listeria strains |
EP3536706A1 (en) | 2018-03-09 | 2019-09-11 | BiOMVis Srl | Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof |
CN110408634B (zh) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
WO2019210034A1 (en) | 2018-04-27 | 2019-10-31 | Advaxis, Inc. | Compositions and methods for evaluating potency of listeria-based immunotherapeutics |
EP3725371A1 (en) | 2019-04-18 | 2020-10-21 | BiOMVis Srl | Method for the production of outer membrane vesicles and immunogenic compositions thereof |
CN110499324A (zh) * | 2019-09-02 | 2019-11-26 | 中生康元生物科技(北京)有限公司 | 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US5552284A (en) | 1991-03-29 | 1996-09-03 | Genentech, Inc. | Detection of interleukin-8 receptors by nudeic acid hybridization |
IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
WO2001072329A1 (en) * | 2000-03-29 | 2001-10-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
AU6501296A (en) | 1995-07-21 | 1997-02-18 | General Hospital Corporation, The | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
EP1320602A2 (en) | 2000-09-21 | 2003-06-25 | The Regents Of The University Of California | Spas-1 cancer antigen |
JP2005527240A (ja) * | 2002-05-29 | 2005-09-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 弱毒リステリア種とこれを使用する方法 |
US20050175625A1 (en) | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
AU2004281834A1 (en) | 2003-10-15 | 2005-04-28 | Cerus Corporation | Listeria-based EphA2 vaccines |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US7858097B2 (en) * | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
EP2860253B1 (en) * | 2006-03-01 | 2018-08-01 | Aduro Biotech, Inc. | Engineered listeria and methods of use thereof |
US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
US20080124354A1 (en) | 2006-07-10 | 2008-05-29 | Yvonne Paterson | Methods for administering tumor vaccines |
JP2010534058A (ja) * | 2007-04-16 | 2010-11-04 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗生物質耐性のないリステリア菌およびその構築および使用方法 |
CN102076843A (zh) * | 2008-05-19 | 2011-05-25 | 艾杜罗生物科技公司 | 包含prfa*突变体李斯特菌的组合物及其使用方法 |
GB201010389D0 (en) | 2010-06-21 | 2010-08-04 | Ist Superiore Sanita | Antibody derivatives |
SI2640842T1 (sl) | 2010-11-17 | 2018-09-28 | Aduro Biotech, Inc. | Postopki in sestavki za induciranje imunskega odziva na EGFRvIII |
CN103687611A (zh) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | 基于李斯特菌属的佐剂 |
KR20140134695A (ko) * | 2012-03-12 | 2014-11-24 | 어드박시스, 인크. | 리스테리아 백신 치료 후 억제 세포 기능 저해 |
-
2013
- 2013-12-27 US US14/142,614 patent/US9663557B2/en not_active Expired - Fee Related
- 2013-12-27 BR BR112015015076A patent/BR112015015076A2/pt active Search and Examination
- 2013-12-27 WO PCT/US2013/078119 patent/WO2014106123A1/en active Application Filing
- 2013-12-27 MX MX2015008329A patent/MX2015008329A/es unknown
- 2013-12-27 EA EA201590397A patent/EA201590397A8/ru unknown
- 2013-12-27 CN CN201380068458.4A patent/CN104955835B/zh not_active Expired - Fee Related
- 2013-12-27 SG SG11201502792TA patent/SG11201502792TA/en unknown
- 2013-12-27 EP EP13869448.4A patent/EP2938627B1/en not_active Not-in-force
- 2013-12-27 SG SG10201700916SA patent/SG10201700916SA/en unknown
- 2013-12-27 CA CA2888727A patent/CA2888727A1/en not_active Abandoned
- 2013-12-27 KR KR1020157015490A patent/KR102160322B1/ko active IP Right Grant
- 2013-12-27 AU AU2013370210A patent/AU2013370210B2/en not_active Ceased
- 2013-12-27 JP JP2015550820A patent/JP2016503655A/ja active Pending
-
2016
- 2016-03-16 HK HK16103082.5A patent/HK1215260A1/zh unknown
-
2017
- 2017-05-18 US US15/599,441 patent/US20170253637A1/en not_active Abandoned
-
2018
- 2018-04-06 JP JP2018074066A patent/JP6671408B2/ja not_active Expired - Fee Related
- 2018-05-21 AU AU2018203555A patent/AU2018203555A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG10201700916SA (en) | 2017-03-30 |
AU2013370210B2 (en) | 2018-06-14 |
JP2018135355A (ja) | 2018-08-30 |
MX2015008329A (es) | 2016-03-01 |
CA2888727A1 (en) | 2014-07-03 |
EP2938627B1 (en) | 2019-03-20 |
BR112015015076A2 (pt) | 2018-10-30 |
HK1215260A1 (zh) | 2016-08-19 |
US20140186387A1 (en) | 2014-07-03 |
KR20150099738A (ko) | 2015-09-01 |
EP2938627A1 (en) | 2015-11-04 |
EP2938627A4 (en) | 2016-12-14 |
JP6671408B2 (ja) | 2020-03-25 |
SG11201502792TA (en) | 2015-05-28 |
KR102160322B1 (ko) | 2020-09-25 |
EA201590397A1 (ru) | 2016-02-29 |
AU2013370210A1 (en) | 2015-06-18 |
US9663557B2 (en) | 2017-05-30 |
WO2014106123A8 (en) | 2016-06-16 |
AU2018203555A1 (en) | 2018-06-07 |
CN104955835B (zh) | 2020-04-17 |
JP2016503655A (ja) | 2016-02-08 |
AU2013370210A8 (en) | 2016-06-23 |
CN104955835A (zh) | 2015-09-30 |
WO2014106123A1 (en) | 2014-07-03 |
US20170253637A1 (en) | 2017-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590397A1 (ru) | Способствующие экспрессии антигенных последовательностей у listeria партнеры для гибридизации, представляющие собой сигнальные пептиды, и способы их получения и применения | |
ZA201607060B (en) | Drug related transgene expression | |
EA201791806A1 (ru) | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов | |
PH12017500483A1 (en) | Method for the absolute qualification of naturally processed hla-restircted cancer peptides | |
MY173004A (en) | Mycobacterial antigen vaccine | |
MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
MX348071B (es) | Variantes de fc. | |
MX2017010159A (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras. | |
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
EA201990959A1 (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
MA39849A (fr) | Souches de listeria utilisées comme vaccin recombinant et procédé de production | |
EA201792671A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака пищевода и других видов рака | |
MX2017005661A (es) | Celulas de mamifero que expresan antigenos de citomegalovirus. | |
MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
NZ730519A (en) | Peptide microarrays and novel biomarkers for celiac disease | |
WO2016073794A8 (en) | Methods of producing two chain proteins in bacteria | |
MX2017015404A (es) | Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas. | |
ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
NZ760789A (en) | Uti fusion proteins | |
WO2018172259A3 (en) | IMPROVED LI VACCINE ADJUVANT | |
WO2015086354A3 (en) | Novel promiscuous hpv16-derived t helper epitopes for immunotherapy | |
WO2020065349A3 (en) | Vaccines and methods | |
WO2016080830A3 (en) | Immunotherapeutic method for treating pancreatic cancer | |
EP2993227A3 (en) | Immunogenic antigens from aspergillus fumigatus |